Brief: Biosergen Says US FDA Grants BSG005 Orphan Drug Status
28/06/2021 06:40
June 28 (Reuters) - Biosergen AB BIOSGN.ST :
* SAID ON SUNDAY BIOSERGEN'S ANTIFUGAL DRUG BSG005 IS
GRANTED
ORPHAN DRUG STATUS IN THE UNITED STATES
* FDA GRANTED BSG005, CO'S ANTIFUNGAL DRUG OF POLYENE
MACROLIDE
CLASS, ORPHAN DRUG STATUS IN THE UNITED STATES
Source text for Eikon: urn:newsml:reuters.com:*:nWkr4wmDD1
Further company coverage: BIOSGN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million